Clinical trials: Head or Neck Cancer
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
The purpose of this study is to see if the investigators can prevent or reduce the severity of the Cetuximab-related acne rash. Two different topical agents will be applied to the skin.
- Trial name
- NCT01931150
- Testing
- Topical Dapsone 5% Gel, Moisturizer, oral antibiotics
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Conditions
- Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer
- Trial name
- NCT05005403
- Testing
- Azirkitug, Budigalimab, Bevacizumab
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 694 people
- Sponsor
- AbbVie
Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic, and potential clinical benefit of PF-07209960…
- Conditions
- Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04628780
- Testing
- PF-07209960
- Where
- 13 sites in United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
Radiation-Induced Mucositis
Steroid-Eluting Stent Implant for the Treatment of Radiation-Related Sinusitis
Sinusitis is one of the most common sequelae after radiotherapy among nasopharyngeal carcinoma patients. While local steroids have been shown to be effective in the management of patients with chronic rhinosinusitis, their role…
- Trial name
- NCT05757479
- Testing
- Steroid-eluting stent implantation, Steroid nasal spray, nasal saline rinses
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma
Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer
The purpose of this study is to investigate a new agent Axitinib in the treatment of head and neck cancer. This is a new drug that is given as a pill twice a day to treat cancer. This is one of the new, "smart" drugs.
- Trial name
- NCT01469546
- Testing
- Axitinib (AG-013736)
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Michigan Rogel Cancer Center
Head and Neck Cancer
Phase II Study of Whole or Partial Parotid Sparing Intensity Modulated Radiotherapy in Patients With Head and Neck Cancers
Phase II and III studies have demonstrated IMRT to be safe and standard practice for head and neck cancers treated with radiotherapy.
- Trial name
- NCT02068313
- Testing
- Toxicity and outcome measures of IMRT
- Where
- 2 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety, determine the recommended Phase 2 dose (RP2D), and assess preliminary clinical activity of GEN1044 in patients with solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT04424641
- Testing
- GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Refractory or Metastatic Esophageal Squamous Cell Carcinoma
A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus radiotherapy and S-1 for treatment of refractory or metastatic esophageal squamous cell carcinoma.
- Trial name
- NCT03320629
- Testing
- apatinib S-1 radiotherapy, S-1 radiotherapy
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Hebei Medical University Fourth Hospital
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from…
- Conditions
- Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
- Trial name
- NCT06029270
- Testing
- Biospecimen Collection, Bone Scan, Carboplatin
- Where
- 95 sites in United States, Australia and 3 more
- Volunteers
- 156 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Oral Mucositis
Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy
The purpose of this study is to evaluate the efficacy and safety of SBG vs placebo on oral mucositis in head and neck cancer patients undergoing radiation therapy.
- Trial name
- NCT00790322
- Testing
- SBG
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Biotec Pharmacon ASA
Recurrent Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
This phase I/II trial studies the side effects and how well bintrafusp alfa and stereotactic body radiation therapy work in treating patients with head and neck squamous cell cancer that has come back (recurrent) or has occurred…
- Trial name
- NCT04220775
- Testing
- Bintrafusp Alfa, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Cancer, Colorectal (Colon or Rectal) Cancer
Quantitative Fluorescence Angiography With ICG for Perfusion Assessment During Surgery
The accurate assessment of intraoperative tissue perfusion is essential in any branch of surgery. Anastomotic leakage (AL) is one of the most feared complications following gastrointestinal surgery, with potentially threatening…
- Trial name
- SPY Q-ICG PAS (NCT05489757)
- Testing
- SPY Portable Handheld Imaging (SPY-PHI) System with SPY-QP Software
- Where
- Italy
- Volunteers
- 196 people
- Sponsor
- IRCCS San Raffaele
Advanced or Metastatic Esophageal Squamous Cell Carcinoma
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
This is a Phase II, randomized, blinded, active-controlled, global, multicenter study designed to evaluate the safety and efficacy of lomvastomig and tobemstomig, compared with nivolumab, in patients with advanced or metastatic…
- Trial name
- NCT04785820
- Testing
- Lomvastomig, Tobemstomig, Nivolumab
- Where
- 52 sites in Argentina, Brazil and 16 more
- Volunteers
- 190 people
- Sponsor
- Hoffmann-La Roche
Recurrent or Metastatic Nasopharyngeal Carcinoma
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
This is a multicenter, open-label, Phase Ib/II study conducted in China to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of YL201 combined with Toripalimab (doublet regimen) or YL201 combined with…
- Trial name
- NCT07258979
- Testing
- YL201, Toripalimab, Cisplatin
- Where
- 20 sites in China
- Volunteers
- 202 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Head and Neck Squamous Cell Carcinoma
A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
The primary objective of the study is to evaluate the comparability of efficacy, safety, and immunogenicity of RPH-002 and Erbitux® when administered in combination with docetaxel and cisplatin as first-line therapy in patients…
- Trial name
- NCT07435324
- Testing
- RPH-002, Erbitux®, Cisplatin
- Where
- 34 sites in Russia, Uzbekistan
- Volunteers
- 161 people
- Sponsor
- R-Pharm
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
This pilot phase II trial studies how well giving bevacizumab and combination chemotherapy together before surgery works in treating patients with locally advanced esophageal or stomach cancer.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT01212822
- Testing
- bevacizumab, oxaliplatin, leucovorin calcium
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fox Chase Cancer Center
Advanced or Metastatic Solid Tumors
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors.
- Trial name
- FLAGSHP-1 (NCT04670679)
- Testing
- ERAS-601, Cetuximab, Pembrolizumab
- Where
- 14 sites in United States, Australia
- Volunteers
- 90 people
- Sponsor
- Erasca, Inc.
Head and Neck Cancer, Oropharyngeal Cancer
Sexual Behavior in Oropharyngeal Patients Versus Head and Neck Cancer Patients, With or Without HPV Infection
Primary Objectives: 1. To determine whether high-risk sexual behaviors are more common in patients with oropharyngeal cancer than in patients with head and neck cancers of other sub-sites. 2.
- Conditions
- Head and Neck Cancer, Oropharyngeal Cancer, Human Papillomavirus Infection
- Trial name
- NCT00508170
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 252 people
- Sponsor
- M.D. Anderson Cancer Center
Colon Cancer, Stomach Tumor
Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients
The aim of this study is to investigate if the systematic implementation of pre-emptive geno- and phenotyping, and therefore a dose reduction based on the French guidelines and the literature during the first month of treatment…
- Conditions
- Colon Cancer, Stomach Tumor, Anal Tumor, Pancreas Cancer
- Trial name
- NCT04269369
- Testing
- 5-Fluorouracil
- Volunteers
- 250 people
- Sponsor
- Jessa Hospital
Head and Neck Cancer
Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer
This study seeks to establish the safety of gemcitabine, paclitaxel and low-dose radiation in recurrent, metastatic head and neck cancer through a two-stage dose escalation study, first with Gemcitabine dose escalation and then…
- Trial name
- NCT00176241
- Testing
- gemcitabine, paclitaxel, radiation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Susanne Arnold
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.